NCT06305234
Phenylketonuria, Phenylketonuria (PKU)
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503.
All
Any
No
Pegvaliase
Observational
200
2024-01-20
2024-08-26
Aurora, Colorado, United States
Chicago, Illinois, United States
New Orleans, Louisiana, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Dallas, Texas, United States
*required fields
"*" indicates required fields